Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

LOUISVILLE, Ky. -- Large tumor size and high disease grade were associated with an increased risk of early cancer-related ...

Merck & Co (MSD), Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

For Merck, the drug that concerns investors is Keytruda. The blockbuster cancer drug faces patent expiration in 2028.

Formycon AG / Preliminary announcement on the disclosure of financial statements Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on IO Biotech (IOBT – Research Report), retaining the price target of ...

In the 630 Battle of al-Qadisiyah, the Arab army emerged victorious and continued its march into Persia, contributing to the spread of Islam beyond West Asia.